首页> 美国卫生研究院文献>Toxicological Sciences >AroER Tri-Screen Is a Biologically Relevant Assay for Endocrine Disrupting Chemicals Modulating the Activity of Aromatase and/or the Estrogen Receptor
【2h】

AroER Tri-Screen Is a Biologically Relevant Assay for Endocrine Disrupting Chemicals Modulating the Activity of Aromatase and/or the Estrogen Receptor

机译:AroER Tri-Screen是与内分泌干扰化学物质有关的生物相关测定可调节芳香酶和/或雌激素受体的活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Endocrine disrupting chemicals (EDCs) interfere with the biosynthesis, metabolism, and functions of steroid hormones, including estrogens and androgens. Aromatase enzyme converts androgen to estrogen. Thus, EDCs against aromatase significantly impact estrogen- and/or androgen-dependent functions, including the development of breast cancer. The current study aimed to develop a biologically relevant cell-based high-throughput screening assay to identify EDCs that act as aromatase inhibitors (AIs), estrogen receptor (ER) agonists, and/or ER antagonists. The AroER tri-screen assay was developed by stable transfection of ER-positive, aromatase-expressing MCF-7 breast cancer cells with an estrogen responsive element (ERE) driven luciferase reporter plasmid. The AroER tri-screen can identify: estrogenic EDCs, which increase luciferase signal without 17β-estradiol (E2); anti-estrogenic EDCs, which inhibit the E2-induced luciferase signal; and AI-like EDCs, which suppress a testosterone-induced luciferase signal. The assay was first optimized in a 96-well plate format and then miniaturized into a 1536-well plate format. The AroER tri-screen was demonstrated to be suitable for high-throughput screening in the 1536-well plate format, with a 6.9-fold signal-to-background ratio, a 5.4% coefficient of variation, and a screening window coefficient (Z-factor) of 0.78. The assay suggested that bisphenol A (BPA) functions mainly as an ER agonist. Results from screening the 446 drugs in the National Institutes of Health Clinical Collection revealed 106 compounds that modulated ER and/or aromatase activities. Among these, two AIs (bifonazole and oxiconazole) and one ER agonist (paroxetine) were confirmed through alternative aromatase and ER activity assays. These findings indicate that AroER tri-screen is a useful high-throughput screening system for identifying ER ligands and aromatase-inhibiting chemicals.
机译:破坏内分泌的化学物质(EDC)会干扰包括雌激素和雄激素在内的类固醇激素的生物合成,代谢和功能。芳香酶将雄激素转化为雌激素。因此,针对芳香化酶的EDC​​会显着影响雌激素和/或雄激素依赖性功能,包括乳腺癌的发展。当前的研究旨在开发一种生物学相关的基于细胞的高通量筛选测定方法,以鉴定出充当芳香酶抑制剂(AI),雌激素受体(ER)激动剂和/或ER拮抗剂的EDC。通过用雌激素反应元件(ERE)驱动的荧光素酶报道质粒稳定转染表达ER阳性,表达芳香化酶的MCF-7乳腺癌细胞,开发了AroER三筛选试验。 AroER三联筛查法可识别:雌激素EDC,可增加萤光素酶信号而无需17β-雌二醇(E2);抗雌激素EDC,抑制E2诱导的荧光素酶信号;以及类似AI的EDC,它们抑制了睾丸激素诱导的萤光素酶信号。该测定法首先以96孔板的形式进行优化,然后小型化为1536孔板的形式。经证实,AroER三重筛选适用于1536孔板格式的高通量筛选,信噪比为6.9倍,变异系数为5.4%,筛选窗口系数(Z-系数)为0.78。该测定表明双酚A(BPA)主要起ER激动剂的作用。在美国国立卫生研究院临床资料库中筛选446种药物的结果显示,有106种化合物可调节ER和/或芳香化酶的活性。其中,通过替代性芳香化酶和ER活性测定证实了两种AI(联苯苄唑和奥西康唑)和一种ER激动剂(帕罗西汀)。这些发现表明,AroER三重筛选是一种有用的高通量筛选系统,可用于识别ER配体和抑制芳香酶的化学物质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号